Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1842, Issue 9, Pages 1770-1782Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbadis.2014.06.008
Keywords
M1; M2; Macrophages; Th17; CD147; Lung interstitial fibrosis
Funding
- National Natural Science Foundation of China [81030058]
- National Science and Technology Major Projects of New Drugs [2012ZX09103301-026]
Ask authors/readers for more resources
Lung interstitial fibrosis is a chronic lung disease, and few effective therapies are available to halt or reverse the progression of the disease. In murine and human lung fibrosis, the expression of CD147 is increased. However, the role of CD147 in lung fibrosis has not been identified, and it remains to be determined whether lung fibrosis would be improved by decreasing the expression of CD147. A murine bleomycin-induced lung interstitial fibrosis model was used in the experiments, and HAb18 inAbs and CsA were administered during the induction of lung fibrosis. In our study, we found that the HAbl8 mAbs markedly reduced the collagen score and down-regulated M1 macrophages and Th17 cells. In vitro, flow cytometry analysis showed that M1 macrophages induced higher Th17 differentiation than M2 macrophages. After treatment with HAbl8 mAbs or after reducing the expression of CD147 by lentivirus interference in M1 macrophages, the level of Th17 cells were significantly inhibited. In conclusion, HAbl8 mAbs or CsA treatment ameliorates lung interstitial fibrosis. CD147 promoted M1 macrophage and induced the differentiation of Th17 cells in lung interstitial fibrosis, perhaps by regulating some cytokines such as IL-6, IL-1 beta, IL-12 and IL-23. These results indicated that CD147 may play an important role in the development of lung interstitial fibrosis. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available